Eton launches Galzin (zinc acetate) capsules for Wilson disease maintenance therapy

Eton Pharmaceuticals, Inc.

Galzin is FDA-approved for maintenance treatment of Wilson disease after chelator therapy; only FDA-approved zinc therapy for Wilson disease.
Exclusive distribution through Optime Care; Eton Cares program offers $0 co-pay, insurance benefits investigation, and educational support.
CEO Sean Brynjelsen states dedicated sales force and patient support aim to expand access beyond unapproved compounded products.
Eton is investing in further R&D to drive meaningful advancements in Wilson disease treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.